NASDAQ
CING

Cingulate Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Cingulate Inc Stock Price

Vitals

Today's Low:
$0.535
Today's High:
$0.6101
Open Price:
$0.5452
52W Low:
$0.664
52W High:
$2
Prev. Close:
$0.573
Volume:
258972

Company Statistics

Market Cap.:
$11.70 million
Book Value:
0.007
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$-8995280
Profit Margin:
0%
Return on Assets TTM:
-79.81%
Return on Equity TTM:
-207.17%

Company Profile

Cingulate Inc had its IPO on 2021-12-08 under the ticker symbol CING.

The company operates in the Healthcare sector and Biotechnology industry. Cingulate Inc has a staff strength of 15 employees.

Stock update

Shares of Cingulate Inc opened at $0.55 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.54 - $0.61, and closed at $0.61.

This is a +6.47% increase from the previous day's closing price.

A total volume of 258,972 shares were traded at the close of the day’s session.

In the last one week, shares of Cingulate Inc have slipped by -4.67%.

Cingulate Inc's Key Ratios

Cingulate Inc has a market cap of $11.70 million, indicating a price to book ratio of 1.2354 and a price to sales ratio of 0.

In the last 12-months Cingulate Inc’s revenue was $0 with a gross profit of $-8995280 and an EBITDA of $-15949158. The EBITDA ratio measures Cingulate Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Cingulate Inc’s operating margin was 0% while its return on assets stood at -79.81% with a return of equity of -207.17%.

In Q1, Cingulate Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

Cingulate Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-1.73 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cingulate Inc’s profitability.

Cingulate Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.4476. Its price to sales ratio in the trailing 12-months stood at 0.

Cingulate Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$7.16 million
Total Liabilities
$6.66 million
Operating Cash Flow
$0
Capital Expenditure
$37135
Dividend Payout Ratio
0%

Cingulate Inc ended 2024 with $7.16 million in total assets and $0 in total liabilities. Its intangible assets were valued at $7.16 million while shareholder equity stood at $81614.00.

Cingulate Inc ended 2024 with $0 in deferred long-term liabilities, $6.66 million in other current liabilities, 1131.00 in common stock, $-73413383.00 in retained earnings and $0 in goodwill. Its cash balance stood at $1.74 million and cash and short-term investments were $1.74 million. The company’s total short-term debt was $5,360,326 while long-term debt stood at $0.

Cingulate Inc’s total current assets stands at $3.75 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $31953.00 compared to accounts payable of $599033.00 and inventory worth $0.

In 2024, Cingulate Inc's operating cash flow was $0 while its capital expenditure stood at $37135.

Comparatively, Cingulate Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.61
52-Week High
$2
52-Week Low
$0.664
Analyst Target Price
$5.88

Cingulate Inc stock is currently trading at $0.61 per share. It touched a 52-week high of $2 and a 52-week low of $2. Analysts tracking the stock have a 12-month average target price of $5.88.

Its 50-day moving average was $0.67 and 200-day moving average was $0.94 The short ratio stood at 4.33 indicating a short percent outstanding of 0%.

Around 2800.7% of the company’s stock are held by insiders while 208.1% are held by institutions.

Frequently Asked Questions About Cingulate Inc

The stock symbol (also called stock or share ticker) of Cingulate Inc is CING

The IPO of Cingulate Inc took place on 2021-12-08

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$4.19
0.08
+1.95%
$1416.15
-29.2
-2.02%
$1.24
0.02
+1.64%
$38.14
0.65
+1.73%
$2.95
-0.05
-1.67%
$0.57
-0
-0.53%
$10.71
-0.02
-0.19%
$12.2
0.34
+2.87%
ABB Ltd (ABB)
$4401.9
-216.95
-4.7%
$2.66
-0.1
-3.62%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company’s lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children, adolescents, and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Address

1901 West 47th Place, Kansas City, KS, United States, 66205